Abstract
Severe adverse reaction to yellow fever (YF) vaccine includes the yellow fever vaccine-associated neurotropic disease. This terminology includes postvaccinal encephalitis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome. The objective of this communication is to report a patient who received a YF vaccine in Argentina and subsequently developed longitudinal myelitis with a symptom that had previously gone unreported in the literature. A 56-year-old man began with progressive paraparesia, urinary retention, and constipation 48 h previous to admission. The patient received YF vaccine 45 days prior to the onset of the symptoms. There was no history of other immunization or relevant condition. MR of the spine showed longitudinal intramedullary hyperintense signal (D5-12) without gadolinium enhancement. A high concentration of YFV-specific IgM vaccine antibody was found in the cerebrospinal fluid (CSF). Serological tests for other flavivirus were negative. A diagnosis of longitudinal myelitis without encephalitis associated with YF vaccine was performed and symptoms improved 5 days later. This is the first report dealing with longitudinal myelitis as a serious adverse event associated with YF vaccination in which confirmation of the presence of antibodies in CSF was found. To date, it is also the first report with serological confirmation in Argentina and in South America. We consider that the present investigation will raise awareness in the region in the reporting of adverse events related to YF vaccine and improve our knowledge of adverse reactions to the vaccine.
Similar content being viewed by others
References
Cetron MS, Marfin AA, Julian KG, et al (2002). Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 51 (RR-17): 1–11; quiz CE1–4.
Fernandes GC, Camacho LA, Sa Carvalho M, Batista M, de Almeida SM (2007). Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005. Vaccine 25: 3124–3128.
Iskander JK, Miller ER, Chen RT (2004). The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 33: 599–606.
Kitchener S (2004). Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 22: 2103–2105.
Lindsey NP, Schroeder BA, Miller ER, et al (2008). Adverse event reports following yellow fever vaccination. Vaccine 26: 6077–6082.
McMahon AW, Eidex RB, Marfin AA, et al (2007). Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25: 1727–1734.
Monath, TP (2004). Yellow Fever Vaccine. In Vaccines, ed. SA Plotkin and WA Orenstein, 1095–1176. Philadelphia: Saunders.
Sanders EJ, Marfin AA, Tukei PM, et al (1998). First recorded outbreak of yellow fever in Kenya, 1992–1993. I. Epidemiologic investigations. Am J Trop Med Hyg 59: 644–649.
Varricchio F, Iskander J, Destefano F, et al (2004). Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 23: 287–294.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.3109/13550284.2010.496630.
Rights and permissions
About this article
Cite this article
Chaves, M., Riccio, P., Patrucco, L. et al. Longitudinal myelitis associated with yellow fever vaccination. Journal of NeuroVirology 15, 348–350 (2009). https://doi.org/10.1080/13550280903062805
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280903062805